Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.